Cargando…
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
Venetoclax is a highly potent, selective BCL2 inhibitor capable of inducing apoptosis in cells dependent on BCL2 for survival. Most myeloma is MCL1-dependent; however, a subset of myeloma enriched for translocation t(11;14) is codependent on BCL2 and thus sensitive to venetoclax. The biology underly...
Autores principales: | Gupta, Vikas A., Barwick, Benjamin G., Matulis, Shannon M., Shirasaki, Ryosuke, Jaye, David L., Keats, Jonathan J., Oberlton, Benjamin, Joseph, Nisha S., Hofmeister, Craig C., Heffner, Leonard T., Dhodapkar, Madhav V., Nooka, Ajay K., Lonial, Sagar, Mitsiades, Constantine S., Kaufman, Jonathan L., Boise, Lawrence H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462405/ https://www.ncbi.nlm.nih.gov/pubmed/33649772 http://dx.doi.org/10.1182/blood.2020007899 |
Ejemplares similares
-
Venetoclax ex vivo functional profiling predicts improved progression-free survival
por: Gupta, Vikas A., et al.
Publicado: (2022) -
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
por: Thijssen, Rachel, et al.
Publicado: (2022) -
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023) -
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022) -
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)